{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:12:27Z","timestamp":1792707147739,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinme.2025.100526","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:42:14Z","timestamp":1761356534000},"page":"100526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4019-3674","authenticated-orcid":false,"given":"Catherine","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-5914","authenticated-orcid":false,"given":"William","family":"Alazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinme.2025.100526_bib0001","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clinme.2025.100526_bib0002","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinme.2025.100526_bib0003","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinme.2025.100526_bib0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"628","key":"10.1016\/j.clinme.2025.100526_bib0005","doi-asserted-by":"crossref","DOI":"10.3399\/bjgp14X682273","article-title":"Ethnicity and the diagnosis gap in liver disease: a population-based study","volume":"64","author":"Alazawi","year":"2014","journal-title":"Br J Gen Pract"},{"issue":"2","key":"10.1016\/j.clinme.2025.100526_bib0006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5005\/jp-journals-10018-1437","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in persons with obesity and type 2 diabetes mellitus: a cross-sectional study","volume":"14","author":"Latif","year":"2024","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"1","key":"10.1016\/j.clinme.2025.100526_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.1016\/j.clinme.2025.100526_bib0008","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinme.2025.100526_bib0009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinme.2025.100526_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.clinme.2025.100526_bib0011","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/jgh.16922","article-title":"Metabolic cause of cirrhosis is the emerging etiology for primary liver cancer in the Asia-Oceania region: analysis of Global Burden of Disease (GBD) Study 2021","volume":"40","author":"Giri","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinme.2025.100526_bib0012","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinme.2025.100526_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/flgastro-2017-100865","article-title":"Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent","volume":"9","author":"De Silva","year":"2018","journal-title":"Frontline Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinme.2025.100526_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur Gastroenterol J"},{"issue":"19","key":"10.1016\/j.clinme.2025.100526_bib0015","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinme.2025.100526_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2025.100526_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinme.2025.100526_bib0018","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a State-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"5","key":"10.1016\/j.clinme.2025.100526_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066493","article-title":"Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol","volume":"13","author":"Brindley","year":"2023","journal-title":"BMJ Open."}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:12:11Z","timestamp":1765948331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211825002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1470211825002441"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100526","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100526"}}